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A major concern during the current severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) pandemic1 is the use of immunosuppressive 
therapies for the treatment of multiple sclerosis (MS) due to an increased risk of 
contracting SARS-CoV-2 and more severe disease. The Society of Italian 
Neurologists (SIN) and the Association of British Neurologists (ABN) MS and 
Neuroimmunology Advisory Group published guidance for the use of current 
disease modifying treatments (DMTs) in MS (Table 1)2. However, taking into 
account, less conservative viewpoints3, the emerging knowledge of the biology of 
SARS-CoV-2, and in particular the role of the immune mechanisms contributing 
to the disease, we propose modification of these guidelines since it is not clear 
that immunosuppression is indeed detrimental in people with MS infected with 
SARS-CoV-2. We are thus proposing a more nuanced approach and that the 
categories of DMTs should be modified based on scientific principles and the 
biology of severe COVID-19 (Table 2).   
 
The immune mechanisms contributing to severe COVID include viral subversion 
of innate immunity and infection of macrophages4, and if similar to SARS CoV, 
may trigger apoptosis of leucocytes leading to lymphopaenia5. The exact 
mechanisms are as yet unclear but suppression of innate responses due to 
modulation of IFN production or receptor signalling, and the apoptotic effects of 
virally encoded proteins have been proposed6. Together these allow widespread 
viral infection, excessive monocyte/macrophage activation and in severe cases a 
cytokine storm triggering severe acute respiratory distress syndrome (ARDS). 
The viral specific CD8 T cell responses appear to eliminate SARS-CoV-2 while viral 
specific antibodies are probably more important to prevent reinfection and create 
long-lasting immunity. A direct role of B cells in the destructive COVID-19 
pathology is unlikely since people with X-linked agammaglobulinemia that recover 
from the COVID-19 pneumonia and lymphopenia without need of intensive care 
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or oxygen ventilation7. In MS, although a single case, ocrelizumab treatment did 
not augment or prolong COVID-19 symptoms8.  
Since many of the MS DMTs have been designed to target the adaptive immune 
response; and for therapeutic effect most likely need to target the memory B 
cells9 it is unlikely that MS DMTs treatment impact on the innate immune 
responses although there is some evidence that fingolmod10 and alemtuzumab11 
impact on the innate immune system. In addition DMTs do not substantially limit 
the antibody responses to SARS-CoV-2 and thus do not pose a risk in the 
development of protective neutralising antibody responses although some DMTs 
will blunt this. 
To avoid ‘throwing the baby out with the bathwater’ we recommend revision of 
the published guidelines2 in light of the role of the immune response in controlling 
SARS-CoV-2 infection (Table 2), the emerging biology of COVID-19, and 
accumulating MS cases reports. We propose that while administration of some 
DMTs should be modified, others may well control the pathogenic immune 
responses during severe COVID-19. For example, whilst in contrast with the 
original guidelines suggest anti-CD20 therapies may increase the risk of 
infection12,13 but this does not necessarily imply a greater risk of poor outcomes 
following infection. In addition, most MS-related DMTs do not particularly target 
the innate immune system and few have any major long-term impact on CD8 T 
cells to limit protection against COVID-19, perhaps with the exception of 
alemtuzumab14. Importantly, MS DMTs do not generally block immature B cell 
development thus allowing antibody production preventing (re)infection, as well 
as response to vaccines when available. However, we recommend adjustments to 
dosing schedules to reduce the chance of infection. 
 
Apart from the reactivation of herpes infections, the moderate 
immunosuppression obtained with most MS DMTs rarely leads to problems 
dealing with viral infections, even in the case of novel viral infections such as 
dengue fever15. With the notable exception of PML and other rare CNS viral 
infections in natalizumab treated patients, which can be de-risked by adopting 
extended interval dosing16, would indicate that the initiation and continuation of 
DMTs in MS does not pose an additional risk of developing more severe COVID-19 
to people with MS. Indeed immunosuppression to treat COVID-19 has been 
proposed as a rational therapeutic approach17,18. This hypothesis is currently 
being tested in several trials to evaluate several immunosuppressive therapies for 
COVID-19, which include fingolimod, a S1P modulator (NCT04280588) and IFN 
(NCT04343768, NCT04350671) that are already widely used to treat MS. Whilst 
the information is only emerging we anticipate that knowledge arising from 
registers collating data on people with MS, DMTs and their responses to SARS-
CoV2 infection (e.g. NCT04354519) will support the hypothesis that moderate 
immunosuppression induced by the DMT used in MS may protect against the 
development of severe COVID-19 infection, which is contrary to current opinion.  
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The accumulating real-world data on the susceptibility of pwMS to develop severe 
COVID-19 being treated with immunosuppressive therapies will allow us to accept 
or reject this hypothesis.  
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Table 1. Society of Italian Neurologists (SIN) and the Association of British 
























Yes Continue  Stop 
Immunomodulatory (not 
immunosuppressive), 




Copaxone Yes Continue  Stop 
Immunomodulatory (not 
immunosuppressive), 
pleiotropic immune effects 
Low Teriflunomide Aubagio Yes Continue  Stop 
Dihydro-orotate 
dehydrogenase inhibitor 





Tecfidera Yes Continue  Stop 
Pleiotropic, NRF2 activation, 
downregulation of nfκβ 
Low Natalizumab Tysabri Yes Continue  Stop 







Yes Continue  Stop 
Selective S1P modulator, 
prevents egress of 





No (Yes) Suspend  Delay Anti-CD20, B-cell depleter 
High* Cladribine Mavenclad No Suspend  Delay 
Deoxyadenosine (purine) 
analogue, adenosine 
deaminase inhibitor, selective 
T & B cell depletion 
High* Alemtuzumab Lemtrada No Suspend  Delay 
Anti-CD52, non-selective 
immune depleter 




*risk refers to acquiring infection during the immunodepletion phase. Postimmune 
reconstitution the risk is low. Modified from Coles et al 20202 
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Class Trade Name 



















see below N/A N/A N/A 











Tysabri Yes Continue 
Continue or miss 













suspension of dosing 
depending on timing 
Intermediate Cladribine Mavenclad Probably 




suspension of dosing 
depending on timing 

















Continue or miss 
infusion depending on 
timing 
High* Mitoxantrone Novatrone No Suspend dosing Suspend dosing 
High* Alemtuzumab Lemtrada No Suspend dosing Suspend dosing 
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High* HSCT - No Suspend dosing Suspend dosing 
 
EID - Extended interval dosing; SID - standard interval dosing  
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